Atrophy-related inflammation CSF markers predict clinical progression in genetic frontotemporal dementia
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Neuroinflammation is increasingly recognised as a key contributor to frontotemporal dementia (FTD) pathophysiology, yet how inflammatory processes relate to neurodegeneration and clinical progression remains poorly defined. This study aimed to identify a multivariate cerebrospinal fluid (CSF) inflammatory signature covarying with brain atrophy, and to determine its relevance to clinical and cognitive outcomes in genetic FTD. We recruited 234 participants (non-carrier controls n=78, presymptomatic carriers n=115, symptomatic carriers n=41) with CSF, MRI, and clinical (CDR (r) + NACC FTLD sum of boxes [CDR-SB]) and executive (Wechsler Adult Intelligence Scale-Revised Digit Symbol Substitution Task [DSST] assessments. A regularised canonical correlation analysis (rCCA) was used to derive a shared protein-brain covariance axis. Participants were followed annually for up to 8.6 years (CDR-SB) and 11.5 years (DSST), and linear mixed-effects models were used to estimate individual rates of clinical progression (CDR slope) and executive decline (DSST slope). The predictive value of the inflammation- and MRI-based profiles for cross-sectional CDR-SB, CDR slope, DSST and DSST slope were tested in linear models. Due to floor effects and violations of parametric assumptions, Bias-corrected and accelerated (BCa) confidence intervals (CI) and bootstrap CIs (95%, 5000 replicates) were utilised as the primary inferential criterion in the 2nd-level linear models; effects were considered non-significant if the 95% BCa CI crossed zero. The rCCA identified a robust inflammation-brain axis (r=0.89, p<0.001), driven by CXCL9, FLT3L, CCL3, and frontotemporal-insular atrophy pattern. In symptomatic carriers, the MRI canonical variate was associated with CDR-SB (beta=3.80, CI: [0.64, 6.20]) at baseline, whereas the inflammatory protein canonical variate was predictive of CDR-SB slope (beta=0.24, CI: [0.02, 0.46]). Whereas both MRI (beta= -7.27, CI:[-14.20, -1.00]) and protein (beta= -7.83, CI:[-14.00, -2.16]) canonical variates were linked to DSST cross-sectionally, but not longitudinally. No significant associations were found in pre-symptomatic carriers or non-carrier controls. A data-driven CSF inflammatory signature, covarying with frontotemporal-insular atrophy, tracks with clinical severity and cognitive impairment in people with genetic FTD, highlighting inflammation as a candidate therapeutic target and progression biomarker in the earliest clinically manifest stages of disease.
Source: medRxiv
Authors: Noah L Shapiro, Kamen Tsvetanov, Kei Onn Lai, Peter Simon Jones, Meira Van Schaik, Emily G Todd, Martina Bocchetta, Arabella Bouzigues, Eve Ferry-Bolder, Eva Cullen, Lucy L. Russell, Phoebe H. Foster, Sophie Farley, Rhian Convery, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Daniela Galimberti, Rik Vandenberghe, Robert Laforce, Elizabeth Finger, Rose Bruffaerts, Maxime Bertoux, Thibaud Lebouvier, Eino Solje, Johannes Levin, Giuseppe Di Fede, Alexander Thompson, Isabelle Le Ber, Raffaella Lara Migliaccio, Peter Kortvelyessy, Matthias L. Schroeter, Giancarlo Logroscino, Markus Otto, Zeljko Uzelac, Ignacio Illan-Gala, Johanna Kruger, Benedetta Nacmias, Alexander Gerhard, Tobias Langheinrich, Simon Ducharme, Isabel Santana, Maria Carmela Tartaglia, Mario Masellis, Alexandre de Mendonca, Caroline Graff, Fermin Moreno, Matthis Synofzik, Barbara Borroni, Raquel Sanchez-Valle, Genetic FTD Initiative (GENFI), James B Rowe, Jonathan D Rohrer, Maura Malpetti
Institutions: University of Cambridge, UK Dementia Research Institute, MRC Cognition and Brain Sciences Unit, Medical Research Council, UCL Queen Square Institute of Neurology, University College London, Brunel University of London, Erasmus MC, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, KU Leuven, Université Laval, Western University, University of Antwerp, Antwerp University Hospital, Hasselt University, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Neurosciences & Cognition, University of Eastern Finland, Kuopio University Hospital, German Center for Neurodegenerative Diseases, LMU Klinikum, Munich Cluster for Systems Neurology, Ludwig-Maximilians-Universität München, Fondazione IRCCS Istituto Neurologico Carlo Besta, University of Oxford, Imperial College London, Centre National de la Recherche Scientifique, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Institut du Cerveau, Charité – Universitätsmedizin Berlin, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig University, University of Bari Aldo Moro, Universität Ulm, Hospital de Sant Pau, Biomedical Research Networking Center on Neurodegenerative Diseases, Centro de Investigación Biomédica en Red, Institut de Recerca Sant Pau, Oulu University Hospital, University of Oulu, University of Florence, University of Manchester, University of Duisburg-Essen, Salford Royal NHS Foundation Trust, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Montreal Neurological Institute and Hospital, McGill University Health Centre, McGill University, Unidade Local de Saúde de Coimbra, Centro de Neurociências e Biologia Celular, University of Coimbra, University of Toronto, Sunnybrook Health Science Centre, Sunnybrook Research Institute, University of Lisbon, Karolinska University Hospital, Karolinska Institutet, Biogipuzkoa Health Research Institute, Donostiako Unibertsitate Ospitalea, Hertie Institute for Clinical Brain Research, University of Tübingen, Centro San Giovanni di Dio Fatebenefratelli, University of Brescia, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Cambridge University Hospitals NHS Foundation Trust
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Wellcome Trust
OpenAlex ID: W7225913660
